Alain Fraisse

ORCID: 0000-0003-1969-421X
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Congenital Heart Disease Studies
  • Cardiac Valve Diseases and Treatments
  • Pulmonary Hypertension Research and Treatments
  • Cardiac Structural Anomalies and Repair
  • Mechanical Circulatory Support Devices
  • Cardiovascular and Diving-Related Complications
  • Coronary Artery Anomalies
  • Infective Endocarditis Diagnosis and Management
  • Aortic Disease and Treatment Approaches
  • Cardiovascular Issues in Pregnancy
  • Cardiovascular Conditions and Treatments
  • Tracheal and airway disorders
  • Kawasaki Disease and Coronary Complications
  • Vascular anomalies and interventions
  • Cardiac Arrhythmias and Treatments
  • Cardiovascular Function and Risk Factors
  • Congenital Diaphragmatic Hernia Studies
  • Cardiac pacing and defibrillation studies
  • Cardiomyopathy and Myosin Studies
  • Renal and Vascular Pathologies
  • Neonatal Respiratory Health Research
  • Heart Failure Treatment and Management
  • Pericarditis and Cardiac Tamponade
  • Transplantation: Methods and Outcomes
  • Vascular Anomalies and Treatments

Guy's and St Thomas' NHS Foundation Trust
2023-2025

Royal Brompton Hospital
2016-2025

Harefield Hospital
2016-2025

Imperial College London
2016-2024

Royal Brompton & Harefield NHS Foundation Trust
2016-2024

St Thomas' Hospital
2024

British Lung Foundation
2023

Lung Institute
2020-2023

Government of the United Kingdom
2023

United Nations Industrial Development Organization
2022

Rationale: Activin A receptor type II-like kinase-1 (ACVRL1, also known as ALK1) mutation is a cause of hereditary hemorrhagic telangiectasia (HHT) and/or heritable pulmonary arterial hypertension (PAH).Objectives: To describe the characteristics patients with PAH carrying an ACVRL1 mutation.Methods: We reviewed clinical, functional, and hemodynamic 32 mutation, corresponding to 9 from French Network 23 literature analysis. These cases were compared 370 (93 bone morphogenetic protein 2...

10.1164/rccm.200908-1284oc article EN American Journal of Respiratory and Critical Care Medicine 2010-01-08

OBJECTIVES: To describe presentation, hospital course, and predictors of bad outcome in multisystem inflammatory syndrome children (MIS-C). METHODS: Retrospective data review a case series meeting the published definition for MIS-C who were discharged or died between March 1, 2020, June 15, from 33 participating European, Asian, American hospitals. Data collected through Web-based survey included clinical, laboratory, electrocardiographic, echocardiographic findings treatment management....

10.1542/peds.2020-024554 article EN PEDIATRICS 2020-11-24

Background The Occlutech Atrial Flow Regulator (AFR) is a self-expandable double-disc nitinol device with central fenestration. Its use has been approved in the adult population heart failure and described for pulmonary hypertension (PH). Only case reports small series have published about its paediatric congenital disease (CHD). Objectives authors sought to investigate feasibility, safety, short-term follow-up of AFR implantation patients CHD or children PH cardiomyopathy. Methods This...

10.3389/fcvm.2023.1332395 article EN cc-by Frontiers in Cardiovascular Medicine 2024-01-15

Background Cytomegalovirus (CMV) frequently is observed in immunocompromised hosts. The aim of this study was to report cases ventilator-associated CMV pneumonia diagnosed by pathologic examination intensive care patients without acquired immunodeficiency syndrome or hematologic malignancy who were not receiving immunosuppressive agents. Methods From June 1, 1989, May 31, 1994, 2,785 hospitalized. During the period, 60 autopsies and 26 open-lung biopsies performed nonimmunocompromised seen...

10.1097/00000542-199602000-00005 article EN Anesthesiology 1996-02-01

* Exposure to bosentan was lower in paediatric pulmonary arterial hypertension (PAH) patients treated with the marketed adult formulation at a dose of about 2 mg kg(-1) when compared PAH patients. In healthy subjects, pharmacokinetics are less than dose-proportional doses >or=500 mg.

10.1111/j.1365-2125.2009.03532.x article EN other-oa British Journal of Clinical Pharmacology 2009-09-01

Evaluate the incidence, diagnosis, and outcome of coronary compression (CC) during right-ventricular outflow tract interventions.The risk factors, outcomes CC percutaneous pulmonary valve implantation are poorly defined.One-hundred consecutive patients (May 2008 to January 2012) undergoing transcatheter treatment in two institutions were studied.CC occurred six (6%) with a right ventricular conduit stenosis, at median age 24.5 (13-49) years. It involved left main artery four originating from...

10.1002/ccd.25471 article EN Catheterization and Cardiovascular Interventions 2014-03-12

The natural history of congenital or childhood non-immune, isolated atrioventricular (AV) block is poorly defined. We retrospectively studied 141 children with isolated, non-immune AV diagnosed in utero, up to 15 years age, at 13 French medical centres, between 1980 and 2009. Patients structural heart disease maternal antibodies were excluded. Atrioventricular was asymptomatic 119 (84.4%) complete 100 (70.9%) patients. There progression 29/41 (70.7%) patients incomplete over 2.8 ± 3.4 (1–155...

10.1093/eurheartj/ehr347 article EN European Heart Journal 2011-09-14

Background: Transcatheter techniques are emerging for left atrial (LA) decompression under venoarterial extracorporeal membrane oxygenation (VA-ECMO). We aimed to assess whether balloon atrioseptostomy (BAS) is a safe and efficient strategy. Methods: All patients who underwent percutaneous static BAS VA-ECMO at four tertiary institutions were retrospectively reviewed. Results: From 2000 2014, was performed in 64 (32 adults 32 children). Indications ECMO support included acute myocarditis...

10.1177/2048872616675485 article EN European Heart Journal Acute Cardiovascular Care 2016-10-14

Background During the severe acute respiratory syndrome Coronavirus 2 pandemic, there has been an increase in hyperinflammatory presentation previously healthy children with a variety of cardiac manifestations. Our objective is to describe manifestations found international cohort 55 pediatric cases multi‐system inflammatory during pandemic. Methods and Results We reviewed data on patients (≤18 years) structurally normal hearts who presented at hospitals United States, Kingdom, Spain,...

10.1161/jaha.120.018007 article EN cc-by-nc-nd Journal of the American Heart Association 2020-09-22

Multisystem inflammatory syndrome in children (MIS-C) is a rare, but severe complication of coronavirus disease 2019 (COVID-19). It develops approximately 4 weeks after acute respiratory 2 (SARS-CoV-2) infection and involves hyperinflammation with multisystem injury, commonly progressing to shock. The exact pathomechanism MIS-C not known, immunological dysregulation leading cytokine storm plays central role. In response the emergence MIS-C, European Academy Allergy Clinical Immunology...

10.1111/pai.13900 article EN Pediatric Allergy and Immunology 2023-01-01

To evaluate the efficacy and safety of intravenous sildenafil for immediate postoperative pulmonary hypertension (PH) in pediatric patients undergoing congenital heart surgery.A double-blind, multicenter, placebo-controlled, dose-ranging, parallel-group trial was conducted. Patients were randomized to one three doses sildenafil, or placebo, a minimum 24 h.The study heavily underpowered. Whereas enrollment 228 (57 per treatment arm) required achieve sample size estimate detect difference...

10.1007/s00134-010-2065-4 article EN cc-by-nc Intensive Care Medicine 2010-11-10

ABSTRACT Objective To identify factors influencing parental decision when a fetal cardiac disease is diagnosed. Method All pregnancies with abnormalities diagnosed at three academic hospitals of Marseille, France, between 2004 and 2008, were retrospectively studied. The association maternal variables (maternal age, parity, ethnicity, gestational age diagnosis, nuchal translucency, gender, chromosomal extra abnormalities, severity the cardiopathy) was tested using univariate multivariate...

10.1002/pd.2923 article EN Prenatal Diagnosis 2012-02-01

Conduit rupture is a serious complication encountered during percutaneous pulmonary valve implantation (PPVI). We sought to evaluate the incidence and predictors of conduit right ventricular outflow tract (RVOT) transcatheter treatment.All consecutive patients who underwent RVOT treatment from May 2008 December 2011 were prospectively studied. Baseline demographics along with incidence, outcomes various therapies reviewed. occurred in nine out 99 (9.09%). All ruptures balloon dilatation....

10.4244/eijy14m09_06 article EN EuroIntervention 2016-01-01

Background: Left ventricular (LV) diastolic dysfunction (DD) carries worse prognosis in childhood. 2-dimensional (2-D) left atrial (LA) strain accurately categorizes DD adults but its role children is unknown. Thus, the aim of this study to investigate whether LA and rate could diagnose classify with dilated (CMD), hypertrophic (HCM) restrictive (RCM) cardiomyopathies (CM). Methods Results: The includes 136 (aged 8.8 ± 6 years): 44 DCM, 40 HCM, 7 RCM 45 healthy controls (CTRL). They...

10.3390/jcm8081243 article EN Journal of Clinical Medicine 2019-08-17

Abstract Background and Aims Transcatheter pulmonary valve implantation (TPVI) is indicated to treat right-ventricular outflow tract (RVOT) dysfunction related congenital heart disease (CHD). Outcomes of TPVI with the SAPIEN 3 that are insufficiently documented were investigated in EUROPULMS3 registry 3-TPVI. Methods Patient-related, procedural, follow-up outcome data retrospectively assessed this observational cohort from 35 centres 15 countries. Results Data for 840 consecutive patients...

10.1093/eurheartj/ehad663 article EN European Heart Journal 2023-10-24
Coming Soon ...